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Molecular design of radiocopperlabelled Affibody molecules
Vladimir Tolmachev 1, Tove J. Grönroos2,3,4, Cheng-Bin Yim2,5, Javad Garousi1, Ying
Yue6, Sebastian Grimm6, Johan Rajander 5, Anna Perols6, Merja Haaparanta-Solin2,7,
Olof Solin2,5,7, Riccardo Ferdani8, Anna Orlova9, Carolyn J. Anderson10 & Amelie Eriksson
Karlström6
The use of long-lived positron emitters 64Cu or 61Cu for labelling of Affibody molecules may improve
breast cancer patients’ stratification for HER-targeted therapy. Previous animal studies have shown
that the use of triaza chelators for 64Cu labelling of synthetic Affibody molecules is suboptimal. In this
study, we tested a hypothesis that the use of cross-bridged chelator, CB-TE2A, in combination with
Gly-Glu-Glu-Glu spacer for labelling of Affibody molecules with radiocopper would improve imaging
contrast. CB-TE2A was coupled to the N-terminus of synthetic Affibody molecules extended either with
a glycine (designation CB-TE2A-G-ZHER2:342) or Gly-Glu-Glu-Glu spacer (CB-TE2A-GEEE-ZHER2:342).
Biodistribution and targeting properties of 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEEZHER2:342 were compared in tumor-bearing mice with the properties of 64Cu-NODAGA-ZHER2:S1,
which had the best targeting properties in the previous study. 64Cu-CB-TE2A-GEEE-ZHER2:342 provided
appreciably lower uptake in normal tissues and higher tumor-to-organ ratios than 64Cu-CB-TE2A-GZHER2:342 and 64Cu-NODAGA-ZHER2:S1. The most pronounced was a several-fold difference in the
hepatic uptake. At the optimal time point, 6 h after injection, the tumor uptake of 64Cu-CB-TE2A-GEEEZHER2:342 was 16 ± 6%ID/g and tumor-to-blood ratio was 181 ± 52. In conclusion, a combination of
the cross-bridged CB-TE2A chelator and Gly-Glu-Glu-Glu spacer is preferable for radiocopper labelling of
Affibody molecules and, possibly, other scaffold proteins having high renal re-absorption.
A high level of human epidermal growth factor receptor type 2 (HER2) expression in breast and gastroesophageal
cancer is a predictor for the response to HER2-targeting therapeutics (antibodies, antibody-drug conjugates,
tyrosine kinase inhibitors)1,2. Several classes of radiolabelled probes for HER2 imaging (antibodies, antibody fragments, engineered scaffold proteins) are under development for non-invasive in vivo assessment of HER2 expression in disseminated cancer3. Affibody molecules are high-affinity binders engineered using a non-antibody
protein scaffold. Due to their small size and high affinity, radiolabelled Affibody molecules can visualize different
cancer-associated molecular target proteins with a high contrast just a few hours after injection4. Clinical data
recently demonstrated that PET using the anti-HER2 68Ga-ABY-025 Affibody molecule permits discrimination
between breast cancer metastases with high and low levels of HER2 expression5. The largest difference between
68
Ga-ABY-025 uptake in HER2-positive and HER2-negative metastases was obtained when images were acquired
at 4 h after injection. We postulated that an extension of the time interval between injection and imaging would
further increase the difference in uptake values in HER2-positive and negative metastases, thereby minimizing
the risk of false-positive findings. Increasing the imaging time post-tracer injection requires a more long-lived
positron-emitting radionuclide than 68Ga (T1/2 = 67.6 min).
The use of longer-lived positron-emitting copper isotopes, 61Cu (T1/2 = 3.4 h) or 64Cu (T1/2 = 12.7 h), may
provide a broader time window for PET imaging of HER2 expression using Affibody molecules. However,
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Figure 1. Structures of the chelators at the N-terminus of CB-TE2A-G-ZHER2:342 (a), CB-TE2A-GEEEZHER2:342 (b) and NODAGA-ZHER2:S1 (c).

besides selection of a nuclide with a suitable half-life and decay scheme, selection of an adequate labelling
strategy is required. Since several studies suggested that the use of derivatives of the triazamacrocyclic chelator NOTA (2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid) provided adequate in vivo stability of a
radiocopper label6–8, we earlier evaluated the use of NOTA and NODAGA (2-(4,7-bis-carboxymethyl-1,4,7-t
riazonan-1-yl)-pentanedioic acid) for labelling of Affibody molecules with 64Cu9. In that study, the chelators
were conjugated to the N-terminus of the synthetic Affibody molecule ZHER2:S1 via an amide bond. Both
64
Cu-NOTA-ZHER2:S1 and 64Cu-NODAGA-ZHER2:S1 accumulated specifically in HER2-expressing xenografts. Surprisingly, the biodistribution pattern of both conjugates differed appreciably from that of other
radiometal-labelled Affibody molecules. There was a rapid decrease of the renal radioactivity and an increase of
radioactivity accumulation in healthy tissues with time, which resulted in a decrease of tumor-to-organ ratios.
This effect was most pronounced for 64Cu-NOTA-ZHER2:S1. One explanation for such an observation was a
release of radiometabolites from kidneys and their re-distribution. This effect was not observed in the majority
of earlier studies because the renal reabsorption of the tested tracer was much lower. This reasoning was corroborated by an observation of a similar effect for another polypeptide with a high renal reabsorption, A20FMDV2,
which was labelled with 64Cu via NOTA monoamide10. Thus, a chelator with a higher metabolic stability or rapid
excretion of radiometabolites is required for labelling of Affibody molecules or other proteins having high renal
reabsorption with radiocopper.
The cross-bridged CB-TE2A (4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane) chelator
provides a stable coupling of radiocopper to peptides and potentially meets our requirements11,12. However, previous studies have demonstrated that the use of chelators increasing the negative charge of the N-terminus of
Affibody molecules is preferable due to reduced hepatic uptake13–15. The complex of Cu(II) with a monoamide
derivative of CB-TE2A has a positive charge, which was considered as a potentially suboptimal property. Still, we
have shown that the placement of a negatively charged triglutamyl spacer between the N-terminus of an Affibody
molecule and a prosthetic group suppresses the hepatic uptake16. This was taken into account while designing
the next generation of Affibody conjugates for labelling with radiocopper (Fig. 1). The aim of this study was to
test the hypotheses that a) the use of monoamide CB-TE2A instead of monoamides of triaza chelators for radiocopper labelling of Affibody molecules prevents deterioration of tumor-to-organ ratios with time, and b) the
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Calculated MW,
Da

Experimental MW,
Da

KD,
pM

Melting
point, °C

CB-TE2A-G-ZHER2:342

7100

7099

60

63

CB-TE2A-GEEE-ZHER2:342

7487

7489

84

64

NODAGA-ZHER2:S1*

6977

6977

90

63

Table 1. Properties of the tracers. *Data from17.

Figure 2. In vitro specificity of 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64Cu-CB-TE2A-G-ZHER2:342 binding
to HER2-expressing SKOV-3 cells. In blocked groups, receptors were pre-saturated by 200-fold excess of
nonlabeled ZHER2:342. Data are presented as the mean of three samples and standard deviation.

use of a triglutamyl spacer between CB-TE2A and the N-terminus of the anti-HER2 Affibody molecule reduces
undesirable hepatic uptake.
To test these hypotheses, we coupled CB-TE2A to the N-terminus of synthetic Affibody molecules
extended either with a glycine (designation CB-TE2A-G-ZHER2:342) (Fig. 1a) or Gly-Glu-Glu-Glu
spacer (CB-TE2A-GEEE-ZHER2:342) (Fig. 1b). The conjugates were labeled with 64Cu. Specificity of
64
Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342 binding to HER2-expressing cells and
their cellular processing after binding was evaluated using SKOV-3 ovarian carcinoma cell line. Biodistribution
of 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342 was compared in BALB/C nu/nu mice
bearing HER2-expressing SKOV-3 or HER2-negative Ramos lymphoma xenografts. The biodistribution was
measured at 2, 6 and 24 h p.i. and compared with biodistribution of 64Cu-NODAGA-ZHER2:S1 (Fig. 1c), which
had the best targeting properties in the previous study.

Results

Preparation and labeling of Affibody molecules. Affibody variants conjugated to the CB-TE2A chelator were successfully prepared by peptide synthesis and their identity was confirmed by mass spectrometry
(Table 1). Purity of greater than 95% was obtained. Melting points (Table 1, Supplemental Figs S1 and S2) of
both variants were close to the melting point of non-modified variant of ZHER2:342 (62.3 °C) and NODAGAZHER2:S1 (63 °C)17. The equilibrium dissociation constants for binding to HER2 were in close range (KD = 60–90
pM) for all Affibody variants used in this study. CD spectra demonstrated high-fidelity refolding of CB-TE2Acontaining Affibody molecules after thermal denaturation (Supplemental Figs S1 and S2).
Both CB-TE2A-G-ZHER2:342 and CB-TE2A-GEEE-ZHER2:342 were successfully labeled with 64Cu by
incubation for 45 min at 95 °C in 0.55 M ammonium acetate, pH 5.6 followed by purification using NAP-5
size-exclusion columns. The isolated labelling yield was 84 ± 5% for 64Cu-CB-TE2A-G-ZHER2:342 and 88 ± 3%
for 64Cu-CB-TE2A-GEEE-ZHER2:342. The radiochemical purity of the conjugates was over 98%. The maximum obtained specific radioactivity was 4.2 MBq/µg (29.6 GBq/µmol) and 3.9 MBq/µg (28.9 GBq/µmol) for
64
Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342, respectively. Challenge with 500-fold
excess of EDTA did not cause any detectable release of radionuclide from conjugates (Supplemental Table S2).
Binding of both 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342 to HER2-expressing
SKOV-3 cells in vitro was efficiently prevented by pre-saturation of receptors by nonlabeled ZHER2:342 (Fig. 2),
which demonstrated its HER2-specific nature. The internalization pattern (Fig. 3) was similar for both conjugates,
and the internalized fraction at 24 h was approximately 25% for both variants. This was higher than the internalized fractions of 64Cu-NODAGA-ZHER2:S1 at this time point (6 ± 1%)9.
Biodistribution Studies.

To test HER2-specificity of 64 Cu-CB-TE2A-GEEE-ZHER2:342 and
Cu-CB-TE2A-G-ZHER2:342 accumulation in tumor in vivo, uptake of both tracers in HER2-positive
(SKOV-3) and HER2-negative (Ramos lymphoma) xenografts was measured at 2 h post injection (p.i.). The
results of the in vivo specificity tests are presented in Fig. 4. Uptake of 64Cu-CB-TE2A-GEEE-ZHER2:342 and
64
Cu-CB-TE2A-G-ZHER2:342 in HER2-positive xenografts was significantly higher than in HER2-negative

64
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Figure 3. Cellular processing of 64Cu-CB-TE2A-GEEE-ZHER2:342 (a) and 64Cu-CB-TE2A-G-ZHER2:342 (b)
during incubation with HER2-expressing SKOV-3 cells. Data are presented as the mean of three samples and
standard deviation. Values are normalized to the maximum cell-associated radioactivity. Error bars might not
be visible because they are smaller than symbols.

Figure 4. Specificity of HER2-targeting in vivo. Biodistribution of 64Cu-CB-TE2A-GEEE-ZHER2:342 (a) or
64
Cu-CB-TE2A-G-ZHER2:342 (b) at 2 h p.i. in mice bearing either HER2-positive xenografts (SKOV-3) or
HER2-negative xenografts (Ramos). The data are presented as mean ±SD for four mice.

xenografts (p < 1 × 10−4). The non-specific uptake in Ramos xenografts was negligible, at 40-to-90-fold lower
than the uptake in SKOV-3 xenografts.
Data comparing the biodistribution of 64Cu-CB-TE2A-G-ZHER2:342, 64Cu-CB-TE2A-GEEE-ZHER2:342
and 64Cu-NODAGA-ZHER2:S1 in mice bearing HER2-positive SKOV-3 xenografts are presented in Table 2. At
2 h after injection, the tumor uptake for all three conjugates was in the range of 14–17% ID/g. There was no significant difference between tumor uptake of the different conjugates at any of time points. Furthermore, there was no
significant difference between tumor uptake at different time points for each conjugate. All variants demonstrated
initially (2 h p.i.) a biodistribution pattern typical for Affibody molecules, i.e. clearance from the majority organs
and tissues (although to different extent) and a high renal re-absorption of the tracers. Low initial radioactivity
in intestines with content indicated negligible contribution of hepatobiliary excretion to clearance. The biodistribution pattern of 64Cu-NODAGA-ZHER2:S1 was in a good agreement with the data published earlier9, i.e.
relatively rapid decrease of radioactivity from kidneys (3-fold between 2 and 24 h) and gradual increase of radioactivity uptake in other normal tissues over time. The biodistribution pattern of 64Cu-CB-TE2A-G-ZHER2:342
and 64Cu-CB-TE2A-GEEE-ZHER2:342 was more typical for other radiometal-labeled Affibody molecules.
Uptake in normal organs and tissues decreased over time for conjugates containing cross-bridged chelators. It
should be noted that the uptake of CB-TE2A-conjugated variants was lower in the majority of normal organs
compared with 64Cu-NODAGA-ZHER2:S1 at 2 h p.i. Renal radioactivity cleared more slowly compared with
64
Cu-NODAGA-ZHER2:S1, at approximately 2-fold between 2 and 24 h after injection. However, there was a clear
difference between 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342. The most prominent
was the difference in hepatic uptake, which was 5–7-fold lower for 64Cu-CB-TE2A-GEEE-ZHER2:342. In addition, the uptake of 64Cu-CB-TE2A-GEEE-ZHER2:342 in lung, spleen, muscle and bone was 1.5–2.5-fold lower.
The biodistribution features of 64Cu-CB-TE2A-G-ZHER2:342, 64Cu-CB-TE2A-GEEE-ZHER2:342
and 64 Cu-NODAGA-ZHER2:S1 had a clear influence on their tumor-to-organ ratios (Table 3).
64
Cu-NODAGA-ZHER2:S1 demonstrated the lowest values at 2 h after injection, and the tumor-to-blood,
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Uptake, % ID/g
2h

6h

64
Cu-CB-TE2ACu-CB-TE2A-G- 64Cu-NODAGAGEEE-ZHER2:342 ZHER2:342
ZHER2:S1

Cu-CB-TE2AGEEE-ZHER2:342

64

24 h

64

Cu-CB-TE2A-GZHER2:342
64

Cu-NODAGAZHER2:S1

64

64
Cu-CB-TE2AGEEE-ZHER2:342

64
Cu-CB-TE2A-GZHER2:342

Cu-NODAGAZHER2:S1

64

Blood

0.15 ± 0.03

0.29 ± 0.08

0.34 ± 0.08c

0.09 ± 0.01

0.11 ± 0.01b

0.43 ± 0.04c

0.07 ± 0.01

0.10 ± 0.01b

0.73 ± 0.04c

Lung

0.6 ± 0.2a

1.2 ± 0.3b

1.8 ± 0.2c

0.42 ± 0.03a

0.70 ± 0.04b

2.3 ± 0.4c

0.34 ± 0.05a

0.61 ± 0.08b

3.6 ± 0.2c

Liver

1.2 ± 0.1a

8.7 ± 0.4b

5.2 ± 0.7c

1.2 ± 0.1a

6.7 ± 0.8b

5.8 ± 0.4c

0.77 ± 0.07a

5.1 ± 0.2b

6.9 ± 0.6c

Spleen

0.40 ± 0.04a

1.0 ± 0.1

0.8 ± 0.2c

0.37 ± 0.02a

0.78 ± 0.02b

0.96 ± 0.08c

0.28 ± 0.02a

0.60 ± 0.09b

1.6 ± 0.2c

Stomach

0.51 ± 0.06a

0.9 ± 0.1

1.8 ± 0.2c

0.38 ± 0.02

0.57 ± 0.03b

2.0 ± 0.2c

0.22 ± 0.04

0.5 ± 0.2b

2.3 ± 0.3c

Kidney

364 ± 41

318 ± 17

349 ± 14

272 ± 18

252 ± 14

295 ± 43

185 ± 15a

141 ± 11b

111 ± 20c

Tumor

14 ± 5

17 ± 2

Muscle

0.12 ± 0.01a

0.20 ± 0.03b

Bone

0.32 ± 0.09a
1.1 ± 0.2a

Intestines*

14 ± 5

16 ± 6

14 ± 3

12 ± 5

11 ± 3

14 ± 4

16 ± 5

0.25 ± 0.02c

0.09 ± 0.01

0.13 ± 0.02b

0.27 ± 0.02c

0.06 ± 0.01

0.10 ± 0.01b

0.38 ± 0.04c

0.63 ± 0.06

0.5 ± 0.1c

0.19 ± 0.03

0.4 ± 0.1

0.6 ± 0.1c

0.14 ± 0.06a

0.39 ± 0.08b

0.8 ± 0.1c

1.7 ± 0.1b

3.5 ± 0.4c

0.8 ± 0.1

1.5 ± 0.1

5.3 ± 0.5c

0.3 ± 0.1a

1.1 ± 0.4b

5.6 ± 0.4c

Table 2. Biodistribution of 64Cu-CB-TE2A-G-ZHER2:342, 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64CuNODAGA-ZHER2:S1 in mice bearing HER2-positive (SKOV-3) xenografts. Data are presented as mean ± SD
for four mice. *Data for intestines with content are presented as %ID per whole sample. aSignificant difference
(p < 0.05) between 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64Cu-CB-TE2A-G-ZHER2:342 at this time point.
b
Significant difference (p < 0.05) between 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-NODAGA-ZHER2:S1 at
this time point. cSignificant difference (p < 0.05) between 64Cu-CB-TE2A-GEEE-ZHER2:342 64Cu-NODAGAZHER2:S1 at this time point.

Tumor-to-organ ratio
2h

6h

24 h

64
64
64
64
64
Cu-CB-TE2ACu-CB-TE2A- 64Cu-NODA
Cu-CB-TE2ACu-CB-TE2A- 64Cu-NODA
Cu-CB-TE2ACu-CB-TE2A- 64Cu-NODA
GEEE-ZHER2:342 G-ZHER2:342 GA-ZHER2:S1 GEEE-ZHER2:342 G-ZHER2:342
GA-ZHER2:S1 GEEE-ZHER2:342 G-ZHER2:342
GA-ZHER2:S1
64

Blood

95 ± 21

61 ± 18

41 ± 8c

185 ± 66

134 ± 36b

29 ± 13c

162 ± 39

140 ± 53b

22 ± 7c

Lung

25 ± 6

14 ± 4

8±2

39 ± 14

20 ± 6

6±3

34 ± 8

23 ± 7

4 ± 1c

Liver

11 ± 3

1.9 ± 0.2

3±1

13 ± 4

2.2 ± 0.7

2.1 ± 0.9

Spleen

35 ± 8

17 ± 3

18 ± 4

44 ± 14

18 ± 4

13 ± 5

Stomach

28 ± 7

19 ± 4

8±2

42 ± 13

25 ± 7

Kidney

0.04 ± 0.01

0.05 ± 0.01

0.04 ± 0.01

0.06 ± 0.02

Muscle

116 ± 35

86 ± 16

57 ± 19c

181 ± 52

27 ± 2

25 ± 5

Bone

a
a
a

46 ± 12a

c
c
c

b

c

a

a
a

87 ± 30a

b

c

2.7 ± 0.8

2.3 ± 0.7c

40 ± 12

24 ± 10

10 ± 3c

6±3

53 ± 15

30 ± 15

0.06 ± 0.01

0.04 ± 0.02

0.06 ± 0.01

0.10 ± 0.03

0.14 ± 0.04c

118 ± 43b

47 ± 20c

194 ± 72

149 ± 59

41 ± 14c

38 ± 11

22 ± 6c

81 ± 7a

36 ± 4b

20 ± 8c

b

c

c
c

15 ± 3

b

a

b

7 ± 2c

Table 3. Comparison of 64Cu-CB-TE2A-G-ZHER2:342, 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64CuNODAGA-ZHER2:S1 tumor-to-organ ratios in nude mice bearing SKOV-3 xenografts. Data are presented as
mean ± SD for four mice. aSignificant difference (p < 0.05) between 64Cu-CB-TE2A-GEEE-ZHER2:342 and
64
Cu-CB-TE2A-G-ZHER2:342 at this time point. bSignificant difference (p < 0.05) between 64Cu-CB-TE2A-GZHER2:342 and 64Cu-NODAGA-ZHER2:S1 at this time point. cSignificant difference (p < 0.05) between 64CuCB-TE2A-GEEE-ZHER2:342 and 64Cu-NODAGA-ZHER2:S1 at this time point.

tumor-to-lung, and tumor-to-spleen ratios decreased over time. 64Cu-CB-TE2A-GEEE-ZHER2:342 demonstrated the best ratios at all time points. Particularly important was the highest tumor-to-liver ratio. At 6 h after
injection, tumor-to-blood and tumor-to-bone ratios for 64Cu-CB-TE2A-G-ZHER2:342 were significantly higher
than at 2 h (p < 0.05), however there was no significant increase of any ratios from 6 to 24 h.

in vivo Imaging Studies.

PET/CT imaging was performed at the same time point as measurements of biodistribution to verify the data and obtain a visual confirmation. The PET imaging results (Fig. 5) confirmed the
ex vivo measurement data. Tumors were clearly visualized by all radiolabelled Affibody molecules. It has to be
noted that the xenografts were small, which might result in an underestimation of the uptake in some tumors
due to partial volume effect18. Indeed, the tumor weights in this study were ranging from 12 to 68 mg. Assuming
a spherical shape for these tumors their diameters ranged approximately from 2.5 mm to 5 mm. The activity
recovery coefficient (RC) of a PET scanner is dependent on the size of the object imaged and the energy of the
β+ particles emitted by a particular radionuclide. Previous investigations19,20 demonstrated that the Inveon PET
provides the RC for 18F varying from 0.15 for objects with 1 mm diameter to 0.97 for 5 mm objects. 64Cu and
18
F have similar β+ energies and one can expect a similarly low recovery for small tumors also for 64Cu. Besides
tumors, very prominent radioactivity uptake was observed for all variants in kidneys and occasionally in bladder.
In addition, high liver uptake was observed for 64Cu-NODAGA-ZHER2:S1 and 64Cu-CB-TE2A-G-ZHER2:342
and accumulation of radioactivity in intestines was visualized for 64Cu-NODAGA-ZHER2:S1 at 6 and 24 h p.i.
64
Cu-CB-TE2A-GEEE-ZHER2:342 provided the best contrast for imaging of HER2-positive xenografts.
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Figure 5. Maximum-intensity-projection PET/CT images of 64Cu-NODAGA-ZHER2:S1, 64Cu-CB-TE2AG-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342 at 2, 6, and 24 h after injection in mice bearing HER2positive SKOV-3 xenografts. Arrows point at tumors. The scale was adjusted to provide clear visualization of
hepatic uptake of 64Cu-CB-TE2A-G-ZHER2:342342 and 64Cu-NODAGA-ZHER2:S1. This resulted in saturation
of tumor images (white spots).

Discussion

Numerous studies have demonstrated that CB-TE2A is one of the best chelators for labelling of peptides with
64
Cu12. The main limitation of its use is the requirement of high temperature for complexation of copper21, which
complicates its use for labelling of proteins with a tertiary structure, e.g. monoclonal antibodies, due to the risk of
denaturation. This is not an issue for Affibody molecules, which are capable of rapid refolding under physiological
conditions22. Although a chelator could interfere with this process, the CD spectra measurements demonstrated
that both CB-TE2A-G-ZHER2:342 and CB-TE2A-GEEE-ZHER2:342 refold with high fidelity after thermal denaturation (Supplemental Figs S1 and S2). After labelling at 95 °C, both 64Cu-CB-TE2A-GEEE-ZHER2:342 and
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Cu-CB-TE2A-G-ZHER2:342 retained the capacity of binding specifically to HER2-expressing cells both in vitro
and in vivo (Figs 2 and 4). Conjugation of CB-TE2A and the amino acid linkers had essentially no effect on the
affinity of the construct, which was in the range of 60–90 pM (Table 1).
The main finding of this study is that the use of CB-TE2A for labelling of Affibody dramatically changes
the pattern of uptake in normal organs compared with the use of NODAGA (Table 2). While the uptake of
radioactivity in blood, liver, lung, spleen, stomach, muscles and bones demonstrated an ascending trend for
64
Cu-NODAGA-ZHER2:S1, the trend was clearly descending for both variants labelled using CB-TE2A. This
resulted in significantly increased tumor-to-organ ratios with time. The effect might be partially explained by
better retention of renal catabolites of 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64Cu-CB-TE2A-G-ZHER2:342
compared to the retention of 64Cu-NODAGA-ZHER2:S1 radiometabolites, as the decrease of renal radioactivity
over time is more pronounced for 64Cu-NODAGA-ZHER2:S1. This is in agreement with the data provided by
Fani and co-workers8 for 64Cu-labed somatostatin antagonists showing higher retention of radioactivity kidneys
when CB-TE2A was used instead of NODAGA. It has to be noted that that absolute renal uptake of somatostatin
analogues was much lower compared to Affibody molecules, and re-distribution of radiometabolites had no
obvious effect of uptake in normal tissues. It is also possible that the radiometabolites are excreted more rapidly in the case of cross-bridged chelators. The high kinetic stability of the 64Cu-CB-TE2A chelate compared to
64
Cu-NODAGA may also account for increased clearance of the CB-TE2A-Affibody constructs from organs other
than the kidneys.
Another essential finding is the role of a linker between a chelate and the N-terminus of Affibody molecules. Incorporation of a chelator/radiometal complex alters the charge of an imaging probe both locally and
globally and affects off-target interactions and consequently on normal tissue uptake. Earlier study suggested
that a negative charge of a radionuclide-chelator complex at the N-terminus of an anti-HER2 Affibody molecule is preferable13–15 and a positively charged monoamide-CB-TE2A/Cu(II) complex might slow down the
blood clearance and increase the hepatic uptake. In fact, the liver uptake of 64Cu-CB-TE2A-G-ZHER2:342 was
approximately four-fold higher than the uptake of the same molecules labelled with 111In using DOTA23. The
present study demonstrated that this effect can be counteracted by the incorporation of a negatively charged
triglutamyl linker. The hepatic uptake of 64Cu-CB-TE2A-GEEE-ZHER2:342 was 5-6-fold lower than the uptake
of 64Cu-CB-TE2A-G-ZHER2:342 (Table 2), which translated into substantially higher tumor-to-liver ratios
(Table 3). This is a critical aspect since both breast and esophageal cancers often have liver metastases24.
It has to be noted that there may be an alternative approach to avoiding the positive charge of the
radiocopper-CB-TE2A complex at N-terminus of affibody molecules. Synthesis of CB-TE2A derivatives featuring
an additional orthogonally protected arm for conjugation has been reported25,26. Such derivatives would provide a
neutral complex with Cu2+. However, the use of oligoglutamate linker provides more straightforward and flexible
way for modification of N-terminal charge for affibody molecules.
Overall, 64Cu-CB-TE2A-GEEE-ZHER2:342 provides the best tumor-to-organ ratios among the tested variants. Biodistribution data suggest that imaging at 6 or 24 h after injection would improve the tumor-to-blood
ratios and therefore increase the sensitivity of imaging. Better retention of Affibody molecules in tumors with
high expression, which was observed both in preclinical27 and clinical studies5, should ensure reliable discrimination between metastases with high and low HER2 expression at later time points.
Recent clinical studies demonstrated that the elevated renal uptake of Affibody molecules5 or nanobodies28
does not complicate PET imaging of metastases in the lumbar area and is associated with an acceptable level of
renal and whole body absorbed doses. This provides a rationale for the use of scaffold protein-based imaging
probes with high renal uptake, such as DARPins29, fibronectin domain derivatives30, or ADAPTs31. Some of them,
e.g. EGFR-targeting Affibody molecules32, would have increased sensitivity of imaging when used several hours
or at the next day after injection. We hope that the results of this study would help to choose the optimal labeling
approach for such imaging agents. Of course, a clinical translation would require a careful optimization of dosimetry for each imaging agent. For example, data from this study suggest that the optimum time point for imaging
would be around 6 h after injection, since there is no significant increase of tumor-to-organ ratios after this. This
indicates that 61Cu (T1/2 = 3.4 h) might be a preferable copper radioisotope for labeling of anti-HER2 Affibody
molecules. This radionuclide might be produced by the 60Ni(d,n)61Cu or 61Ni(p,n) 61Cu nuclear reactions using
low-energy cyclotrons available at PET centers33,34. Preliminary estimations suggest that the renal and whole body
doses would be similar in this cases to doses due to imaging using 68Ga-labeled Affibody molecules.
In conclusion, this study confirmed our hypotheses that the use of monoamide CB-TE2A instead of monoamino derivatives of triaza chelators for radiocopper labelling of Affibody molecules prevents deterioration of
tumor-to-organ ratios with time, and the use of a triglutamyl spacer between CB-TE2A and the N-terminus of the
anti-HER2 Affibody molecule reduces undesirable hepatic uptake. The combination of CB-TE2A and a negatively
charged Gly-Glu-Glu-Glu linker is a suitable variant for labelling of Affibody molecules with radiocopper.
64

Methods

Radioactivity measurements, analysis and data treatment. VDC-405 ionization chamber
(Veenstra Instruments) was used for radioactivity measurement during formulation of solutions for injections.
Radioactivity of samples from in vitro and in vivo studies was measured using an automated gamma spectrometer (Wizard2, PerkinElmer). Purity, yield and stability of radiolabelled Affibody molecules were measured using
radio-instant thin-layer chromatography (radioITLC) with ITLC-SG strips (Agilent). The strips were developed
with 0.2 M citric acid, pH 2. Radioactivity distribution along the strips was measured using BAS-TR2025 imaging
plates (Fuji Photo Film Co.) scanned with an FLA-5100 scanner (both from Fuji Photo Film Co). RadioITLC
analysis was validated using a blank experiment and radio-reversed phase high performance liquid chromatography (radio-HPLC). For radio-HPLC, a Jupiter Proteo C12 column (4.6 × 250 mm) was eluted with a linear
CH3CN/H2O gradient (10–70% CH3CN in 12 min) in 0.1% trifluoroacetic acid at a flow rate of 1.0 mL/min.
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The data are presented as the mean +/− standard deviation. An unpaired two-tailed t-test was used to find a
significant difference (P < 0.05) between two sets of data. One-way ANOVA analysis with Bonferroni’s multiple
comparison test using Prism 5 software (GraphPad Software) was used to evaluate differences between more than
two sets.

Synthesis and characterization of Affibody molecules.

The chelator CB-TE2A was synthesized as
previously described11.
The Affibody molecule ZHER2:342 with the sequence VENKFNKEMRNAYWEIALL PNLNNQQKRAFIRSLY
DDPSQSANLLAEAKKLNDAQAPK was synthesized using standard Fmoc chemistry on a 433A Peptide
Synthesizer (Applied Biosystems) as described earlier17. The N-terminus of the synthesized Affibody molecule was extended manually by coupling of Gly (variant G-ZHER2:342) or Gly-Glu-Glu-Glu sequence (variant
GEEE-ZHER2:342). The CB-TE2A chelator (10 mol equivalents) was conjugated to the peptide using 10 mol equivalents of N′,N′-dicyclohexylcarbodiimide and N-ethyldiisopropylamine. The molar excess of the chelator was used
to ensure nearly 100% conjugation yield. Deprotection of the protecting groups and release of the peptide from the
resin were achieved by treatment with a mixture of H2O/TIS/TFA (2.5:2.5:95) for 2 h at RT. The deprotected peptide
was extracted between H2O and tert-butyl methyl ether, followed by lyophilization of the aqueous phase. Analysis of
the conjugates was performed by RP-HPLC using a SOURCETM 5RPC column, a 20 min gradient of 20–50% B (A:
0.1%TFA-H2O, B: 0.1%TFA-CH3CN) and a flow rate of 1 mL/min. The purification was performed using a Zorbax
CB300-C18 column. Mass spectrometric analysis was carried out on a Bruker MALDI mass spectrometer (CCA
matrix) to confirm the protein mass.
The affinity of CB-TE2A-GEEE-ZHER2:342 and CB-TE2A-G-ZHER2:342 binding to the extracellular
domain of HER2 (R&D systems) was measured in duplicate with concentrations of 0.25, 0.5, 1, 2, 3, 5, and 10 nM
using Biacore 2000 as described earlier17. The curve fitting (Langmuir 1:1 binding model) was performed using
BiaEval software (Biacore AB, Sweden).
Circular dichroism studies were performed with 40 µM protein in PBS (pH 7.4) using a Jasco J-810 spectropolarimeter17. For the variable temperature measurements, the signal was recorded at 221 nm and the temperature
was increased from 20 to 90 °C at a rate of 5 °C/min. Circular dichroism spectra were recorded from 250 to
195 nm at 20 °C before and after the melting.
The Affibody molecule NODAGA-ZHER2:S1 containing the NODAGA chelator conjugated via amide bond
at the N-terminus was synthesized, purified and characterized as described earlier17. This Affibody molecule has
a sequence AEAKYAKEMRNAYWEIALLPNL TNQQKRAFIRKLYDDPSQSSELLSEAKKLNDSQAPK, and biodistribution of 68Ga- and 111In-labeled DOTA conjugated ZHER2:S1and ZHER2:342 are very similar35,36.
Copper-64 was produced using the 64Ni(p,n)64Cu nuclear reaction and separated and purified by anion
exchange chromatography, as previously described37. The radionuclide was prepared as a solution in 0.04 M HCl
with effective specific radioactivity of 3 TBq/μmol at the end of bombardment.
For radiolabeling, Affibody molecule, 50 µg in 50 µL 0.55 M ammonium acetate, pH 5.6, was mixed with 150–
270 MBq 64CuCl2 in 10 µL 0.04 M HCl, and the mixture was incubated for 45 min at 95 °C. A 500-fold excess of
Na4EDTA (10 mg/mL in water, 137 µL) was added to the mixture followed by additional incubation at 95 °C for
10 min. The radiolabeled Affibody molecules were purified using disposable NAP-5 size-exclusion columns (GE
Healthcare). The label stability was tested by incubation of labeled Affibody molecules with a 500-fold excess of
Na4EDTA during 1 h.
NODAGA-ZHER2:S1 was labeled with 64Cu for comparative in vivo studies as described earlier9. As
HER2-postitive cells, SKOV-3 ovarian carcinoma cell line (1.2 × 106 receptors per cell)22 was used for in vitro and
in vivo studies. Ramos lymphoma cell line was used for implantation of HER2-negative xenografts. Both cell lines
were purchased from American Type Tissue Culture Collection (ATCC) via LGC Standards (Teddington, UK)
and cultivated according to ATCC recommendations.
The specificity of 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64Cu-CB-TE2A-G-ZHER2:342 binding to
HER2-expressing SKOV-3 cells was evaluated by a saturation assay using a 200-fold molar excess of non-labelled
ZHER2:342 Affibody molecules9.
To evaluate internalization, SKOV-3 cells were incubated with the conjugates (1 nM) and the internalized
radioactivity was measured at 1, 2, 4, 8 and 24 h using a modified acid wash method, as described earlier38. The
cells were incubated at 37 °C with the labeled compounds (concentration 1 nM). A set of three dished was used
for each data point. The incubation medium from a dishes was removed. The cells were washed ice cold medium.
The membrane-bound radioactivity was removed by treatment with 0.5 mL of 0.2 M glycine buffer containing 4 M
urea, pH 2.0, for 5 min on ice. Dishes were additionally washed with 0.5 mL acidic buffer and by 1 mL PBS, and the
fractions were pooled. To collect radioactivity internalized by the cells, the cells were treated them with 0.5 mL of
1 M NaOH at 37 °C for 0.5 h. The dishes were additionally washed with 0.5 mL NaOH solution followed by 1 mL
PBS. The radioactivity in acidic (cell bound) and alkaline (internalized) fraction was measured.

Biodistribution Studies. Animals were cared for in compliance with the guidelines of the International
Council of Laboratory Animal Science. All animal procedures were approved by the Animal Ethics Committee
of the Provincial Government of Southern Finland, and performed following the guidelines of the European
Community Council Directives 86/609/EEC.
HER2-positive xenografts were obtained by subcutaneous inoculation of 1 × 107 SKOV-3 cells in female
BALB/C nu/nu mice (Scanbur, 8 weeks old at arrival). HER2-negative control tumors were obtained by inoculation of 1 × 107 Ramos lymphoma cells. Experiments were performed 20 days after implantation. The average
tumor weight was 38 ± 22 mg at the time of the experiment.
A group of four mice per data point was used for ex vivo measurements. Mice bearing SKOV-3 xenografts
were injected via the tail vein with 64Cu-CB-TE2A-G-ZHER2:342, 64Cu-CB-TE2A-GEEE-ZHER2:342 or
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Cu-NODAGA-ZHER2:S1 (450 kBq in 100 µL per mouse). The injected protein dose was adjusted to 5 µg (0.7
nmol). Biodistribution was measured 2, 6, and 24 h post-injection. Mice bearing HER2-negative Ramos lymphoma xenografts were injected with the same amounts of protein and radioactivity, and biodistribution was
measured 2 h after injection. The animals were exsanguinated under anesthesia, the organs and tissues of interest
were excised and their weight and radioactivity were measured. Radioactivity of gastrointestinal tract (with content) was also measured to evaluate hepatobiliary excretion.

64

in vivo Imaging Studies.

SKOV-3 (n = 2) xenograft-bearing mice were injected via the tail vein with
Cu-CB-TE2A-G-ZHER2:342 (13.1 ± 0.9 MBq, 5 µg, 100 µL). 64Cu-CB-TE2A-GEEE-ZHER2:342 (16.6 ± 0.05
MBq, 5 µg, 100 µL) or 64Cu-NODAGA-ZHER2:S1 (12.3 ± 0.9 MBq, 5 µg, 100 µL). Mice were anesthetized using
2.5% isoflurane/O2, and positioned on a heating pad two at a time in a PET/CT scanner (Siemens Medical
Solutions, Inc.) for CT acquisition (10 min) and PET scan in list mode (20 min). Mice were scanned at 2, 6,
and 24 h post-injection. PET images were reconstructed using an FBP algorithm of two iterations, followed by
maximum a posteriori (MAP, 18 iterations) integrative algorithms (Inveon Acquisition Workplace, version 2.0;
Siemens Preclinical Solutions). Data were decay-corrected to the time of injection.
64
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